| Literature DB >> 25347679 |
Colm G Connolly1, Amanda Bischoff-Grethe2, Stephan J Jordan2, Steven Paul Woods3, Ronald J Ellis4, Martin P Paulus5, Igor Grant3.
Abstract
BACKGROUND: Risky decision-making is commonly observed in persons at risk for and infected with HIV and is associated with executive dysfunction. Yet it is currently unknown whether HIV alters brain processing of risk-taking decision-making.Entities:
Mesh:
Year: 2014 PMID: 25347679 PMCID: PMC4210250 DOI: 10.1371/journal.pone.0111583
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of the HIV- and HIV+ groups.
| Characteristic | HIV- | HIV+ | DoF | Statistic | P-value | Effect Size | Significance |
|
| |||||||
| Number of Participants | 19 | 21 | 1.00 | χ2 = 0.03 | 0.87 | ||
| Gender (M/F) | 18/1 | 19/2 | 1.00 | χ2≈0 | 1.00 | ||
| Sexual Orientation (MSM/Heterosexual) | 5/14 | 18/3 | 1.00 | χ2 = 12.07 | <0.001 | *** | |
| Handedness (R/L) | 18/1 | 18/3 | 1.00 | χ2 = 0.18 | 0.67 | ||
| Age at time of scanning (years) | 38.1±2.5 (23–54) | 40.8±2.6 (23–58) | 37.99 | t = −0.74 | 0.46 | ||
| Years of education | 14.4±0.5 (11–20) | 13.8±0.5 (9–18) | 37.97 | t = 0.85 | 0.40 | ||
| Days between initial and scanning visits† | 58±37.1 (19–124) | 77±44.5 (23–733) | NA | W = 135.5 | 0.09 | g = 0.34 | |
|
| 3.00 | χ2 = 3.85 | 0.28 | ||||
| African-American | 2.5 | 12.5 | |||||
| Hispanic | 12.5 | 10 | |||||
| Other | 0 | 2.5 | |||||
| White | 32.5 | 27.5 | |||||
|
| 1.00 | χ2 = 5.05 | 0.02 | ||||
| East | 10 | 3 | |||||
| West | 9 | 18 | |||||
|
| |||||||
| East | 2011/02/03–2011/08/10 | 2010/06/05–2010/08/14 | |||||
| West | 2011/04/01–2012/04/04 | 2011/01/03–2012/03/19 | |||||
|
| |||||||
| Wide Range Achievement Test | 106.1±2.7 (94–134) | 99.7±2.2 (85–134) | 35.81 | t = 1.85 | 0.07 | g = 0.60 | |
| Global Deficit Score† | 0.2±0.2 (0–1) | 0.3±0.3 (0–1.9) | NA | W = 151.5 | 0.20 | PS = 0.38 | |
| Global Deficit Score Impaired (n) | 3 | 7 | 1.00 | W = 0.84 | 0.36 | ||
| Speeded Information Processing | 51.8±1.9 (38.8–69.5) | 48.1±1.9 (31.5–63.8) | 37.95 | t = 1.38 | 0.17 | g = 0.40 | |
| Verbal Fluency | 49.2±1.9 (38–66.7) | 46.5±1.6 (35.3–64.7) | 35.92 | t = 1.10 | 0.28 | g = 0.30 | |
| Learning | 46.8±2.2 (20–58) | 42.3±1.6 (24.5–56) | 32.91 | t = 1.63 | 0.11 | g = 0.50 | |
| Working Memory | 51.7±2.3 (28.5–68) | 47±1.5 (33.5–59.5) | 31.28 | t = 1.68 | 0.10 | g = 0.50 | |
| Executive Functions | 51.1±2.2 (34.5–67.8) | 46±2 (29.2–68.5) | 37.07 | t = 1.7 | 0.10 | g = 0.50 | |
| Motor Skills | 52.4±2.4 (38–71.5) | 49.7±2.5 (33.5–72) | 38.00 | t = 0.78 | 0.44 | g = 0.20 | |
| BDI-II (at initial visit) | 1.7±0.6 (0–7) | 10.9±2.2 (0–35) | 22.53 | t = −4.07 | 0.00 | g = −1.3 | *** |
| BDI-II (at time of scan) | 1.7±0.8 (0–14) | 8.6±2 (0–35) | 25.71 | t = −3.16 | <0.01 | g = −1.00 | ** |
| POMS (at time of scan) | 55.8±3.3 (25–78) | 68.8±6.6 (27–146) | 29.02 | t = −1.75 | 0.09 | g = −0.50 | |
| Lifetime MDD Diagnosis (n) | 3 | 11 | 1.00 | χ2 = 4.37 | 0.04 | * | |
| Current MDD Diagnosis (n) | 0 | 5 | 1.00 | χ2 = 3.22 | 0.07 | ||
|
| |||||||
| Sexual Sensation Seeking Scaled (Mean) | 1.8±0.1 (1.2–2.6) | 2.1±0.1 (1–3.3) | 34.04 | t = −1.79 | 0.08 | g = −0.60 | |
| Non Sexual Sensation Seeking Scaled (Mean) | 2.3±0.1 (1.5–3.5) | 2±0.1 (1.3–3) | 36.32 | t = 2.02 | 0.05 | g = −0.60 | * |
| Sexual Compulsivity Scaled (Mean) | 1.1±0 (1–1.6) | 1.4±0.1 (1–2.4) | 26.01 | t = −2.33 | 0.03 | g = −0.70 | * |
|
| |||||||
| Total | 59.3±2.3 (46–79) | 61.1±2.4 (45–85) | 38.00 | t = −0.54 | 0.59 | ||
| Attentional Subscale | 15.3±0.7 (9–20) | 16.6±0.8 (9–22) | 37.86 | t = −1.16 | 0.25 | ||
| Motor Subscale | 18.1±0.8 (13–30) | 19.1±0.9 (13–27) | 37.96 | t = −0.84 | 0.41 | ||
| Non Planning Subscale | 26±1.2 (16–38) | 25.5±1.1 (16–38) | 37.05 | t = 0.32 | 0.75 | ||
|
| |||||||
| Duration of Infection (months) | Not applicable | 96.9±22.8 (1.6–318.1) | |||||
| Nadir CD4 Count† | Not applicable | 250±174.9 (3–763) | |||||
| Current CD4 Count† | Not applicable | 426±277.2 (81–1061) | |||||
| Plasma Viral Load (% Detectable) | Not applicable | 42.90 | |||||
| AIDS (%) | Not applicable | 47.60 | |||||
| ART Currently Prescribed (%) | Not applicable | 71.43 | |||||
| ART Past Use (%) | Not applicable | 9.52 | |||||
| ART Never Used (%) | Not applicable | 19.05 | |||||
|
| |||||||
| Fagerström Test for NicotineDependence (Total Score) | 1.6±0.6 (0–8) | 1.8±0.6 (0–9) | 38 | t = −0.22 | 0.82 | ||
| Nicotine Dependence (%) | 0 | 5 (23.8) | 1 | χ2 = 3.22 | 0.07 | ||
| Alcohol Abuse (%) | 1 (5.3) | 0 | 1 | χ2≈0 | 0.96 | ||
| Alcohol Dependence | 0 | 0 | |||||
| Cannabis Abuse | 0 | 0 | |||||
| Cannabis Dependence | 0 | 0 | |||||
|
| |||||||
| Alcohol Abuse (%) | 5 (26.3) | 5 (23.8) | 1 | χ2≈0 | 1 | ||
| Alcohol Dependence (%) | 2 (10.5) | 1 (4.8) | 1 | χ2 = 0.01 | 0.93 | ||
| Cannabis Abuse (%) | 5 (26.3) | 4 (19.0) | 1 | χ2 = 0.03 | 0.86 | ||
| Cannabis Dependence (%) | 0 | 1 (4.8) | 1 | χ2≈0 | 1 | ||
| Cocaine Abuse | 0 | 0 | |||||
| Cocaine Dependence | 0 | 0 | |||||
| Methamphetamine Abuse | 0 | 0 | |||||
| Methamphetamine Dependence | 0 | 0 | |||||
| Hallucinogen Abuse (%) | 1 (5.3) | 0 | 1 | χ2≈0 | 0.96 | ||
| Hallucinogen Dependence (%) | 0 | 1 (4.8) | 1 | χ2≈0 | 1 | ||
| Inhalant Abuse | 0 | 0 | |||||
| Inhalant Dependence | 0 | 0 | |||||
| Opioid Abuse | 0 | 0 | |||||
| Opioid Dependence | 0 | 0 | |||||
| PCP Abuse | 0 | 0 | |||||
| PCP Dependence | 0 | 0 | |||||
| Sedative Abuse (%) | 0 | 1 (4.8) | 1 | χ2≈0 | 1 | ||
| Sedative Dependence | 0 | 0 | |||||
| MDMA Abuse | 0 | 0 | |||||
| MDMA Dependence (%) | 0 | 1 (4.8) | 1 | χ2≈0 | 1 | ||
Mean ± SEM (min - max) or median ± MAD (min - max) if indicated by †.
Statistic: W, Wilcox rank sum test; χ2, χ2 test for equality of proportions; t, Student’s T test.
Effect size: g, Hedge’s g; PS, probability of superiority.
Dates are in year/month/day format.
Abbreviations: SEM, standard error of the mean; MAD, median absolute deviation; MSM, men who have sex with men; BDI-II, Beck Depression Inventory II, POMS, Profile of Mood States; MDD, Major Depressive Disorder; CD4, Cluster of Differentiation 4; AIDS, Acquired Immunodeficiency Syndrome; ART, Anti-retroviral therapy; MDMA, 3,4-methylenedioxymethylamphetamine; DoF, degrees of freedom; NA, not applicable; M, male; F, female; R, right; L, left. '*' p<0.05, '**' p<0.01.
Figure 1An illustration of four different trial types from the risky gains task: (A) lose 80, (B) win 20, (C) win 40 and (D) lose 40.
The blue arrow indicates participant response to select the value on screen.
Functional brain regions identified as showing risk-related differences between the HIV- and HIV+ groups while they performed the risky gains task.
| Structure | Hemisphere | BA | Volume | Center of Mass | Average | ||
| (µL) | X | Y | Z | F-valuea | |||
| Anterior Cingulate | R | 24/32 | 21,249 | −5 | −16 | 27 | 7.16 |
| Middle Frontal Gyrus | L | 9 | 11,043 | 38 | −15 | 33 | 6.92 |
| Middle Frontal Gyrus | R | 9/46 | 9,450 | −41 | −20 | 29 | 6.52 |
| Thalamus | L | 3,510 | 10 | 30 | 1 | 6.45 | |
| Lentiform Nucleus | L | 13 | 3,348 | 20 | −12 | 1 | 6.22 |
| Claustrum | R | 2,376 | −26 | −19 | 6 | 5.98 | |
| Inferior Parietal Lobule | L | 40 | 2,349 | 41 | 65 | 44 | 5.42 |
| Superior Frontal Gyrus | R | 10 | 1,917 | −26 | −54 | 5 | 7.00 |
Center-of-mass coordinates, in radiological convention, are in the MNI152 standard space and structure labels are from the Talairach & Tournoux atlas [150]. BA, Brodmann Area; L, Left; R, Right. a F(1, 36).
Figure 2Brain regions identified by the between-group whole-brain analysis of the general linear test of risky (40, 80) versus safe (20) choices.
The bar charts indicate percentage signal change and are the breakdown of responses within group and by choice (20, 40, 80) in these regions. Error bars indicate the standard error of the mean. L, left; R, right.
Figure 3Within the HIV+ group, graphs of the relationship between nadir CD4 count and a subset of the voxels in each of the clusters depicted in Figure 2 and Table 2.
The subset of voxels is the overlap between the clusters showing between-group task related functional differences and those clusters identified by the robust regression analysis conducted only within the HIV+ group. The black line is the robust regression line on the difference between risky and safe responses. The red and blue lines are robust regression lines of the safe and risky components of the black line. L, left; R, right; Inf, Inferior; Sup, Superior; Gy, Gyrus.
Figure 4Within the HIV+ group, graphs of the relationship between Kalichman Sexual Compulsivity Scaled Mean and a subset of the voxels in three of the clusters depicted in Figure 2 and Table 2.
The subset of voxels is the overlap between the clusters showing between-group task related functional differences and those clusters identified by the robust regression analysis conducted only within the HIV+ group. The black line is the robust regression line on the difference between risky and safe responses. The red and blue lines are robust regression lines of the safe and risky components of the black line. L, left; R, right; Sup, Superior; Gy, Gyrus.
Overlap between regions showing task related between-group differences (from Table 2) and regions identified by robust regression relating brain activity to neuromedical and neuropsychiatric measures.
| Structure | Hemisphere | BA | Volume | Average | Average |
| (µL) |
| β value | |||
|
| |||||
| Anterior Cingulate | R | 24/32 | 1,215 | −2.37 | −0.0011 |
| Middle Frontal Gyrus | L | 9 | 216 | −2.89 | −0.0009 |
| Middle Frontal Gyrus | R | 9/46 | 621 | −2.57 | −0.0011 |
| Thalamus | L | 756 | −2.71 | −0.0024 | |
| Lentiform Nucleus | L | 13 | 108 | −2.84 | −0.0012 |
| Claustrum | R | 378 | −1.52 | −0.0006 | |
| Inferior Parietal Lobule | L | 40 | 594 | −2.21 | −0.0013 |
| Superior Frontal Gyrus | R | 10 | 486 | −2.39 | −0.0011 |
|
| |||||
| Anterior Cingulate | R | 24/32 | 3,456 | −2.61 | −0.42 |
| Thalamus | L | 81 | −2.42 | −0.61 | |
| Superior Frontal Gyrus | R | 10 | 783 | −2.64 | −0.51 |
Term refers to the neuropsychiatric or neuromedical explanatory variable in the regression model from which the clusters were derived. Polarity refers to the sign (positive or negative) of the regression coefficients from which the cluster was generated. BA, Brodmann Area; L, Left; R, Right. a t(17).